Home › Compare › MRUS vs STAG

MRUS vs STAG: Dividend Comparison 2026

MRUS yields 2.22% · STAG yields 3.44%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MRUS wins by $4.6K in total portfolio value
10 years
MRUS
MRUS
● Live price
2.22%
Share price
$90.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$23.0K
Annual income
$256.54
Full MRUS calculator →
STAG
STAG Industrial Inc.
● Live price
3.44%
Share price
$36.06
Annual div
$1.24
5Y div CAGR
0.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$18.3K
Annual income
$462.70
Full STAG calculator →

Portfolio growth — MRUS vs STAG

📍 MRUS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMRUSSTAG
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MRUS + STAG cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
MRUS pays
STAG pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MRUS
Annual income on $10K today (after 15% tax)
$188.89/yr
After 10yr DRIP, annual income (after tax)
$218.06/yr
STAG
Annual income on $10K today (after 15% tax)
$292.69/yr
After 10yr DRIP, annual income (after tax)
$393.29/yr
At 15% tax rate, STAG beats the other by $175.24/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MRUS + STAG for your $10,000?

MRUS: 50%STAG: 50%
100% STAG50/50100% MRUS
Portfolio after 10yr
$20.6K
Annual income
$359.62/yr
Blended yield
1.74%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRUS right now

MRUS
Analyst Ratings
10
Buy
12
Hold
Consensus: Hold
Price Target
$97.00
+7.8% upside vs current
Range: $97.00 — $97.00
Altman Z
34.5
Piotroski
3/9
STAG
Analyst Ratings
9
Buy
9
Hold
3
Sell
Consensus: Buy
Price Target
$45.00
+24.8% upside vs current
Range: $39.00 — $59.00
Altman Z
1.2
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MRUS buys
0
STAG buys
0
No recent congressional trades found for MRUS or STAG in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMRUSSTAG
Forward yield2.22%3.44% ✓
Annual dividend / share$2.00 ✓$1.24
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0.3% ✓
Portfolio after 10y$23.0K ✓$18.3K
Annual income after 10y$256.54$462.70 ✓
Total dividends collected$2.4K$4.0K ✓
Payment frequencyquarterlymonthly
SectorStockREIT
Analyst consensusHoldBuy
Analyst price target$97.00 ✓$45.00

Year-by-year: MRUS vs STAG ($10,000, DRIP)

YearMRUS PortfolioMRUS Income/yrSTAG PortfolioSTAG Income/yrGap
1← crossover$10,922$222.22$10,665$345.38+$257.00 → MRUS
2$11,914$226.84$11,365$358.01+$549.00 → MRUS
3$12,979$231.24$12,099$370.76+$880.00 → MRUS
4$14,123$235.43$12,870$383.63+$1.3K → MRUS
5$15,351$239.43$13,678$396.60+$1.7K → MRUS
6$16,669$243.22$14,526$409.67+$2.1K → MRUS
7$18,082$246.82$15,413$422.82+$2.7K → MRUS
8$19,598$250.24$16,343$436.05+$3.3K → MRUS
9$21,224$253.47$17,315$449.35+$3.9K → MRUS
10$22,966$256.54$18,332$462.70+$4.6K → MRUS

MRUS vs STAG: Complete Analysis 2026

MRUS — Stock

Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Full MRUS Calculator →

STAG — REIT

STAG Industrial, Inc. (NYSE: STAG) is a real estate investment trust focused on the acquisition and operation of single-tenant, industrial properties throughout the United States. By targeting this type of property, STAG has developed an investment strategy that helps investors find a powerful balance of income plus growth.

Full STAG Calculator →
📬

Get this MRUS vs STAG comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MRUS vs SCHDMRUS vs JEPIMRUS vs OMRUS vs KOMRUS vs MAINMRUS vs PLDMRUS vs EQRMRUS vs VICI

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.